Material Agreements (Details) $ in Thousands								2 Months Ended	3 Months Ended	12 Months Ended			17 Months Ended	26 Months Ended
	Mar. 02, 2023 USD ($)	Nov. 01, 2022 USD ($)	Oct. 26, 2022 USD ($)	Sep. 26, 2022 USD ($)	May 17, 2022 USD ($) vestingPeriod day	Nov. 03, 2020 USD ($)	Apr. 01, 2016 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Feb. 20, 2019 USD ($)	Dec. 31, 2022 USD ($)	Mar. 03, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										$ 47,680	$ 50,832
Pro rata portion of target bonus					$ 280
Cash payment representing 90 days of base pay					$ 150
Days of base pay | day					90
Severance costs					$ 263
Number of installments | vestingPeriod					3
Severance period (in months)					18 months
Coverage duration					18 months
Consulting fee					$ 10
Assertio Holdings, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from collaborators			$ 9,000
Contingent consideration, milestone payments		$ 6,000
First Seven Months
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Severance costs					53
Eighth Month
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Severance costs					70
Ninth through Eighteenth Month
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Severance costs					$ 88
License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										2,351	5,380
Royalty
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										$ (916)
Royalty | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues												$ 8,000
Commercial Exploitation Agreement with Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement term										7 years
Automatic renewal period of agreement										1 year
Commercial Exploitation Agreement with Indivior | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Automatic renewal period of agreement	1 year
Commercial Exploitation Agreement with Indivior | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Notice period of intent not to renew agreement										1 year
Supplemental Agreement with Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues													$ 40,750
License Agreement with Sunovion Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues							$ 22
Milestone payment, no longer receivable							23,000
License Agreement with Sunovion Pharmaceuticals, Inc. | Royalty
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues									$ 8,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues							17,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones | License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues												$ 4,000
License Agreement with Sunovion Pharmaceuticals, Inc. Upfront
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues							$ 5,000
Marathon Pangolin Royalty LLC | Monetization Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenue						$ 40,000		$ 10,000						$ 50,000
Proceeds from debt, contingent on additional milestones						75,000
Marathon Pangolin Royalty LLC | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenue						$ 125,000
Atnahs Pharma UK Limited | License & Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenue				$ 3,500
Haisco Pharmaceutical Group Co., Ltd, Upfront Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, receivable, after allowance for credit loss															$ 7,000
CLA KemPharm | License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues											$ 2
Suboxone Agreements Settlement | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 11,482
Deferred revenue, revenue recognized	$ 5,482